European Multicenter Study on Analytical Performance of DxN Veris System HCV Assay

ABSTRACT The analytical performance of the Veris HCV Assay for use on the new and fully automated Beckman Coulter DxN Veris Molecular Diagnostics System (DxN Veris System) was evaluated at 10 European virology laboratories. Precision, analytical sensitivity, specificity, and performance with negative samples, linearity, and performance with hepatitis C virus (HCV) genotypes were evaluated. Precision for all sites showed a standard deviation (SD) of 0.22 log10 IU/ml or lower for each level tested. Analytical sensitivity determined by probit analysis was between 6.2 and 9.0 IU/ml. Specificity on 94 unique patient samples was 100%, and performance with 1,089 negative samples demonstrated 100% not-detected results. Linearity using patient samples was shown from 1.34 to 6.94 log10 IU/ml. The assay demonstrated linearity upon dilution with all HCV genotypes. The Veris HCV Assay demonstrated an analytical performance comparable to that of currently marketed HCV assays when tested across multiple European sites.

[1]  John E. Bennett,et al.  Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .

[2]  P. Pancholi,et al.  Performance of the Abbott RealTime and Roche Cobas TaqMan Hepatitis C Virus (HCV) Assays for Quantification of HCV Genotypes , 2012, Journal of Clinical Microbiology.

[3]  B. Frémont,et al.  SUMMARY OF SAFETY AND EFFECTIVENESS DATA , 2002 .

[4]  H. Fleury,et al.  Evaluation of the VERSANT HCV RNA 3.0 Assay for Quantification of Hepatitis C Virus RNA in Serum , 2002, Journal of Clinical Microbiology.

[5]  H. Masur,et al.  Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Aasld Idsa Hcv Guidance Panel.  Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus , 2015, Hepatology.

[7]  B. Gärtner,et al.  Differences between Two Real-Time PCR-Based Hepatitis C Virus (HCV) Assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and One Signal Amplification Assay (Versant HCV RNA 3.0) for RNA Detection and Quantification , 2008, Journal of Clinical Microbiology.

[8]  G. Colucci,et al.  Improved COBAS TaqMan Hepatitis C Virus Test (Version 2.0) for Use with the High Pure System: Enhanced Genotype Inclusivity and Performance Characteristics in a Multisite Study , 2007, Journal of Clinical Microbiology.

[9]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[10]  Roger Williams.  Global challenges in liver disease , 2006, Hepatology.

[11]  J. Pawlotsky,et al.  Performance of the Abbott Real-Time PCR Assay Using m2000sp and m2000rt for Hepatitis C Virus RNA Quantification , 2009, Journal of Clinical Microbiology.

[12]  H. Rosen.  Clinical practice. Chronic hepatitis C infection. , 2011, The New England journal of medicine.

[13]  S. Zeuzem,et al.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection. , 2011, Journal of hepatology.